Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study
Year: 2019
Type: article
Authors: Jerald P. Radich, David M. Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin García Gutierrez, Norbert Gattermann, Philipp D. Le Coutre, Bruno Martino, Susanne Saussele, Francis J. Giles, Giuseppe Saglio, Manu Sondhi, Kaushal Mishra, Paola Aimone, Andreas Hochhaus
Institutions: Fred Hutch Cancer Center, South Australia Pathology, Semmelweis University, Hospital Universitario de Gran Canaria Doctor Negrín, Gdańsk Medical University, Aarhus University Hospital, St. James's Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Düsseldorf University Hospital, Charité – Universitätsmedizin Berlin, Azienda ospedaliera "Bianchi-Melacrino-Morelli", Heidelberg University, Medizinische Fakultät Mannheim, University of Turin, Novartis (Switzerland), Jena University Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2970596852